Workout before breakfast to get better results, says study

Agencies
October 20, 2019

Washington D.C., Oct 20: Your blood sugar levels can easily be controlled by changing a few eating and exercising schedules, suggest researchers.

The six-week study involved thirty men classified as obese or overweight and compared results from two intervention groups (who ate breakfast before/after exercise) and a control group (who made no lifestyle changes), found that people who performed exercise before breakfast burned double the amount of fat than the group who exercised after breakfast.

They found that increased fat use is mainly due to lower insulin levels during exercise when people have fasted overnight, which means that they can use more of the fat from their fat tissue and the fat within their muscles as a fuel.

To test proof-of-principle the initial study involved only men, but future studies will look to translate these findings for different groups including women.

Whilst this did not lead to any differences for weight loss over six weeks, it did have 'profound and positive' effects on their health because their bodies were better able to respond to insulin, keeping blood sugar levels under control and potentially lowering the risk of diabetes and heart disease.

Building on emerging evidence that the timing of meals in relation to exercise can shift how effective exercise is, the team behind this study wanted to focus on the impact on the fat stores in muscles for individuals who either worked out before or after eating and the effect this had on insulin response to feeding.

"Our results suggest that changing the timing of when you eat in relation to when you exercise can bring about profound and positive changes to your overall health," explained Dr Javier Gonzalez of the Department for Health at the University of Bath.

"We found that the men in the study who exercised before breakfast burned double the amount of fat than the group who exercised after. Importantly, whilst this didn't have any effect on weight loss, it did dramatically improve their overall health," added Dr Javier Gonzalez.

The study was published in the 'Journal of Clinical Endocrinology & Metabolism'.

"The group who exercised before breakfast increased their ability to respond to insulin, which is all the more remarkable given that both exercise groups lost a similar amount of weight and both gained a similar amount of fitness. The only difference was the timing of the food intake," said Dr Javier Gonzalez.

Over the six-week trial, the scientists found that the muscles from the group who exercised before breakfast were more responsive to insulin compared to the group who exercised after breakfast, in spite of identical training sessions and matched food intake.

The muscles from those who exercised before breakfast also showed greater increases in key proteins, specifically those involved in transporting glucose from the bloodstream to the muscles.

For the insulin response to feeding after the 6-week study, remarkably, the group who exercised after breakfast were in fact no better than the control group. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
September 18,2020

cancer.JPG

Ludhiana, Sept 18: DMCH Cancer Care Centre in collaboration with American Oncology Institute recently started a new diagnostic service (PSMA-PET Scan) in treating various prostate cancer.

Prostate cancer is the most common cancer in men and one of the leading causes of cancer death. Prostate Specific Membrane Antigen (PSMA ) is highly expressed in prostate cancer and its expression increases with tumour aggressiveness, metastatic disease and disease recurrence.

Secretary of DMCH Managing Society, Sh. Prem Kumar Gupta said, “Very few facilities in the region have this state-of-art facility and will be of great benefit for the patients.” He further added, “DMCH Cancer Care Centre is always in the process of acquiring new techniques and facilities for diagnosing and treating various cancer diseases. The availability of this facility will go a long way to help both patients and clinicians in knowing about the proper stage of prostate cancer, thereby helping patients with better outcome.”

Dr. Puneet Bhutani from the Department of Nuclear Medicine, American Oncology Institute stated, “This is a major milestone in diagnosis of prostate cancer. The procedure of diagnosing prostate cancer through PSMA-PET Scan is more accurate method for early detection of recurrent disease. It allows the oncologists to treat patients at an early stage and provide them a better treatment outcome.”

About American Oncology Institute:

American Oncology Institute is the leading cancer care provider across South Asia operating a chain of cancer hospitals in multiple cities across South Asia. AOI today is a wholly owned subsidiary of Varian Medical Systems (NYSE: VAR).

The team of clinical, paraclinical and healthcare operations experts pride themselves with the aim of closing the gap between standards of cancer care in South Asia and the developed cancer hospitals in the West. AOI provides comprehensive cancer management that is powered by clinical excellence, world class technology as well as best in class clinical pathways and protocols for treatment planning and execution, providing best in-class quality in cancer care across South Asia.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
September 30,2020

A new research adds to the growing body of evidence that airborne transmission of COVID-19 spreads more quickly in enclosed spaces.

Researchers were able to link a community outbreak of COVID-19 in China to a source patient who likely spread the virus to fellow bus riders through the bus's air conditioning system.

"Our study provided epidemiologic evidence of transmission over long distances, which was likely airborne," said study lead author Ye Shen from University of Georgia in the US.

According to the study, published in the journal JAMA Internal Medicine, it was largely believed that close contact through droplets is a major route of transmission for COVID-19.

"However, the widely adopted social distancing and hand washing did not effectively prevent the transmission globally. Instead, the number of new COVID-19 cases increased steadily," said Shen.

The research team worked with epidemiologists from two regional Centers for Disease Control and Prevention in China to trace infections following a large outdoor worship event in Zhejiang province.

Some of the attendees, it turns out, took two buses to the event creating a unique natural experiment for the researchers.

Both buses had closed windows and had air conditioning running, said Changwei Li, study co-author, but one bus carried a patient infected with the virus, and the other did not.

Of the passengers who later got sick, the majority of them rode on the same bus as the source patient.

Even though the two groups later mixed in with the larger crowd at the worship event, the number of new cases attributed to the event were much lower, suggesting that the bus was the major point of transmission.

Further, some of the bus passengers who later showed symptoms of COVID-19, the authors found, were not sitting close to the infected passenger.

These findings highlight scenarios where COVID-19 could be spread through fine aerosol particles being circulated in an enclosed space.

"Understanding the transmission routes of COVID-19 is critical to contain the pandemic, so that effective prevention strategies can be developed targeting all potential transmission routes," said Shen.

"Our findings provide solid support for wearing face covering in enclosed environments with poor ventilation," the study author wrote.

Recently, another study published in the journal Proceedings of the National Academy of Sciences, found that ordinary conversation creates a conical 'jet-like' airflow that quickly carries a spray of tiny droplets from a speaker's mouth across metres of interior space.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
September 29,2020

Pune, Sept 29: A further collaboration among the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective COVID-19 vaccines for India and low-and middle income countries.

This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August.

The arrangement again provides an option to secure additional doses if the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator sees a need for it. The collaboration will provide upfront capital to SII to help it increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be distributed at scale to LMICs as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.

"The collaboration further bolsters our fight against COVID-19. Through the avid support of Gavi and the Bill & Melinda Gates Foundation, we will now manufacture and deliver up to an additional 100 million doses of immunogenic and safe-proven future Covid-19 vaccines to India and low- and middle-income countries in 2021," said Adar Poonawalla, CEO of Serum Institute of India.

He added, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that the future vaccines reach the remotest part of the world providing full immunization coverage in a bid to contain the spread of the pandemic."

The funding will help accelerate the manufacturing by SII for candidate vaccines licensed from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification.

The vaccines will have a ceiling price of US$3 per dose, a price enabled by investments made by partners such as the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill and Melinda Gates Foundation and SII. "This is vaccine manufacturing for the Global South, by the Global South, helping us to ensure no country is left behind when it comes to access to a Covid-19 vaccine," said Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance.

"The momentum behind our effort to ensure global, equitable access to Covid-19 vaccines is really building. Last week, we were able to announce the historic number of countries that are now signed up to the COVAX Facility, today we can announce further doses of safe, effective vaccines that will be reserved specifically for low- and middle-income countries. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines; this collaboration brings us another step closer to achieving this goal."

The Gavi COVAX AMC, which is currently seeking at least US$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine doses. The Gavi Board has agreed upon the final list of 92 countries that will be supported by the Gavi COVAX AMC. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries.

Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi COVAX AMC. These countries align with SII's licensing agreements with the two partners. The collaboration between Gavi, SII, and the Gates Foundation supports the efforts of the ACT Accelerator's vaccines pillar, also known as COVAX, co-led by Gavi, CEPI and the World Health Organization (WHO), to accelerate the development of COVID-19 vaccines and ensure rapid, global access to them.

Decisions around investment in manufacturing are taken in close collaboration between these three lead organisations of the COVAX pillar. Under the COVAX umbrella, Gavi is coordinating the COVAX Facility, which provides governments with the opportunity to benefit from a large portfolio of Covid-19 candidate vaccines using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand.

So far 73 higher-income economies have formally committed to join the Facility, in addition to the 92 low- and middle-income economies that are eligible for support from the Gavi COVAX AMC. The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further US$150 million to Gavi, bringing the total funding provided through this collaboration to US$300 million.

This will be used to support the Serum Institute of India to manufacture potential vaccine candidates, and for future procurement of vaccines for India and low- and middle-income countries via Gavi's COVAX AMC.

The deal is additional to a Memorandum of Understanding between AstraZeneca and Gavi, announced in June, which will commit an additional 300 million doses of AstraZeneca's candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification. These two deals can help assure access to early doses for the most vulnerable on a truly global scale.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.